NEO (NeoGenomics) Total Debt per Share: $3.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEO NeoGenomics Inc NEO
73 GF Score
Price $15.93
GF Value $15.99
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Total Debt per Share?

NeoGenomics NEO +4.22% 73 Total Debt per Share is $3.51 as of Jun. 2026. GuruFocus rates NEO with a GF Score™ of 73/100 and a GF Value™ of $15.99 (Fairly Valued). The stock has 6 warning signs investors should review.

$3.51 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. NeoGenomics's Total Debt Per Share for the quarter that ended in Jun. 2026 was $3.51.

NeoGenomics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Total Debt per Share Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.94 4.81 4.80 4.72 3.17

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 3.18 3.17 3.15 3.51
NEO
73GF Score
NeoGenomics Inc NEO
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Total Debt per Share Calculation

NeoGenomics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(404.7+4.8)/129.0
=3.17

NeoGenomics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(442.9+5.4)/127.9
=3.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $3.51 mean?
NeoGenomics (NEO) has a Total Debt per Share of $3.51 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Total Debt per Share too high?
NeoGenomics' current Total Debt per Share is $3.51. Overall, NeoGenomics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Total Debt per Share compare to WGS and CDNA?
NeoGenomics' Total Debt per Share of $3.51 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Diagnostics & Research company?
A good Total Debt per Share depends on the Medical Diagnostics & Research industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on NeoGenomics and its competitors. NeoGenomics's current Total Debt per Share is $3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Fairly Valued. The stock's GF Value™ is $15.99, compared to a current price of $15.93 — trading 0.4% below its estimated fair value. The current Total Debt per Share is $3.51. NeoGenomics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For NeoGenomics (NEO), the current Total Debt per Share is $3.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of $15.93 is trading 0.4% below its estimated GF Value™ of $15.99. GuruFocus considers NeoGenomics to be Fairly Valued.

Key valuation signals for NEO:

  • Total Debt per Share: $3.51
  • GF Value™: $15.99 vs. price of $15.93 (0.4% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
73GF Score

Get the complete analysis for NEO

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.93
Price
$15.99
GF Value